Protection of hematopoietic cells against combined O6-benzylguanine and chloroethylnitrosourea treatment by mutant forms of O6-methylguanine DNA methyltransferase

  • D. A. Williams
  • , R. Maze
  • , C. Kurpad
  • , A. Pegg
  • , L. C. Erickson

    Research output: Contribution to journalArticlepeer-review

    9 Scopus citations

    Abstract

    This report demonstrates that expression of the P140A O6-methylguanine DNA methyl transferase (MGMT) mutant via retrovirus-mediated gene transfer leads to significant, but modest, resistance of cells to both 6-benzylguanine (6-BG) depletion and treatment with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). Expression of the P140A/G156A double mutant appeared to be associated with reduced or unstable protein in hematopoietic cells. Bone Marrow Transplantation (2000) 25, Suppl. 2, S105–S109.

    Original languageEnglish (US)
    Pages (from-to)S105-S109
    JournalBone Marrow Transplantation
    Volume25
    DOIs
    StatePublished - May 2000

    All Science Journal Classification (ASJC) codes

    • Hematology
    • Transplantation

    Fingerprint

    Dive into the research topics of 'Protection of hematopoietic cells against combined O6-benzylguanine and chloroethylnitrosourea treatment by mutant forms of O6-methylguanine DNA methyltransferase'. Together they form a unique fingerprint.

    Cite this